What is Our Group?
Operating as a premier medical entity, Our Group specializes in the comprehensive management of lower intestinal tract pathologies. The practice distinguishes itself through a multidisciplinary approach to treating complex conditions such as colorectal cancer, diverticulitis, and pelvic floor disorders. By integrating advanced robotic surgery techniques with a strong emphasis on preventative screening protocols, the firm maintains a high standard of patient-centric care. Their market position is defined by a commitment to clinical excellence and the utilization of minimally invasive procedures that facilitate accelerated recovery times for their patient base.
How much funding has Our Group raised?
Our Group has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2021): $150K with participation from PPP
Key Investors in Our Group
PPP
Public-Private Partnership
What's next for Our Group?
With the infusion of this recent capital, Our Group is strategically positioned to scale its clinical infrastructure and invest in next-generation surgical technologies. The firm's roadmap likely involves deepening its penetration in the regional market by optimizing patient throughput and potentially expanding its specialized service offerings. As the healthcare sector continues to prioritize value-based care and surgical precision, the organization's focus on robotic-assisted interventions will serve as a critical differentiator. Future growth will be predicated on maintaining high-quality outcomes while scaling the practice to meet the increasing demand for specialized colorectal health services in the Midwest.
See full Our Group company page
